CYP3A型
最大值
体内
假阳性悖论
药理学
药代动力学
CYP3A4型
药品
化学
计算生物学
体外
细胞色素P450
医学
生物
数学
统计
生物化学
微粒体
新陈代谢
生物技术
作者
Heidi J. Einolf,L Chen,Odette A. Fahmi,Christopher R. Gibson,R. Scott Obach,Mohamad Shebley,J Silva,Michael Sinz,Jashvant D. Unadkat,L Zhang,Ping Zhao
标识
DOI:10.1038/clpt.2013.170
摘要
Several drug-drug interaction (DDI) prediction models were evaluated for their ability to identify drugs with cytochrome P450 (CYP)3A induction liability based on in vitro mRNA data. The drug interaction magnitudes of CYP3A substrates from 28 clinical trials were predicted using (i) correlation approaches (ratio of the in vivo peak plasma concentration (Cmax) to in vitro half-maximal effective concentration (EC50); and relative induction score), (ii) a basic static model (calculated R3 value), (iii) a mechanistic static model (net effect), and (iv) mechanistic dynamic (physiologically based pharmacokinetic) modeling. All models performed with high fidelity and predicted few false negatives or false positives. The correlation approaches and basic static model resulted in no false negatives when total Cmax was incorporated; these models may be sufficient to conservatively identify clinical CYP3A induction liability. Mechanistic models that include CYP inactivation in addition to induction resulted in DDI predictions with less accuracy, likely due to an overprediction of the inactivation effect.
科研通智能强力驱动
Strongly Powered by AbleSci AI